Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

Paradigm Communications

- PMLiVE

Oral hepatitis C regimens tackle advanced liver disease

 New data released at the International Liver Congress by AbbVie, Merck & Co and Gilead

- PMLiVE

WHO raises red flag on hepatitis C drug pricing

Warns about cost of Gilead’s Sovaldi and J&J’s Olysio

Bristol-Myers Squibb (BMS) building

BMS’ oral hepatitis C regimen gets breakthrough status

Combines daclatasvir and asunepravir

- PMLiVE

EU clears Gilead’s hepatitis C therapy Sovaldi

Region’s first all-oral treatment approved to treat the virus

- PMLiVE

Boehringer’s faldaprevir set for rapid review in Europe

More competition in emerging hepatitis C market

- PMLiVE

CHMP recommends Gilead’s sofosbuvir for hep C

Set to be first interferon-free treatment regime

Bristol-Myers Squibb (BMS) building

BMS exits hep C, diabetes and neuroscience drug discovery

Will discontinue 'broad-based discovery work' in the therapy areas

- PMLiVE

Merck stakes a claim to all-oral hepatitis C market

Positive data for interferon-free regimen

- PMLiVE

Incivek decline forces Vertex job cuts

370 positions to be axed

- PMLiVE

Gilead’s sofosbuvir aces FDA advisory committee

On track for hepatitis C approval in US

- PMLiVE

J&J wins FDA panel backing for hepatitis C drug

Simeprevir would challenge Victrelis and Incivek if approved

- PMLiVE

Janssen buys hepatitis C candidate from GSK

J&J subsidiary acquires rights to NS5A inhibitor

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links